Using multiple datasets from real-world evidence and completed trials, a machine learning model using routine blood and clinical data is shown to be predictive of patient response to immune checkpoint inhibitor therapy, across cancer types and outperforming standard biomarkers.
- Seong-Keun Yoo
- Conall W. Fitzgerald
- Diego Chowell
